- Correction
- Open access
- Published:
Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
BMC Cancer volume 23, Article number: 740 (2023)
The Original Article was published on 26 August 2020
Correction: BMC Cancer 20, 806 (2020)
Following publication of the original article [1], the authors want to clarify the wording of two sentences.
In the line of the study procedures section “In total, 44 patients will be enrolled per group. After n = 18 patients have been enrolled to the HYPO- or CON-treatment arm, respectively, an interim efficacy analysis for the respective arm will be conducted based on the objective response rate (ORR) at 12 weeks after first durvalumab administration”, the sentence was refined to “[…] the objective response rate (ORR), when the 18th patient in each arm has undergone first radiographic assessment (at 12 weeks after first durvalumab administration).”
In the study endpoint section, in the line “The ORR evaluated 12 weeks after first durvalumab administration (according to RECIST 1.1) is set as the primary efficacy endpoint.”, the sentence changed to “The ORR according to RECIST 1.1 is set as the primary efficacy endpoint.”
References
Bozorgmehr F, Chung I, Christopoulos P, et al. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer. 2020;20:806. https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-020-07264-8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-020-07264-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Bozorgmehr, F., Chung, I., Christopoulos, P. et al. Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer 23, 740 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-023-11270-x
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-023-11270-x